0%, non-SVR 75.4%, 5-years survival rate: SVR 100.0%, non-SVR 53.8%). Rapid virological response (RVR) and Complete early virological response (cEVR) were obtained in 5.9% (3/51 therapy sessions) and 13.7% (7/51) of patients treated with PEG-IFN/R. On the other hand, RVR rate was 100.0% (4/4) with PEG-IFN/R plus teraprevir and 100.0% (8/8) with

PEG-IFN/R plus simeprevir, and cEVR rate was 100.0% (4/4) with PEG-IFN/R plus teraprevir and 80.0% (4/5) with PEG-IFN/R plus simeprevir. Conclusion The achievement of SVR by PEG-IFN/R therapy in HCV-related LDLT patients bring good prognosis after LDLT and the PEG-IFN/R plus protease inhibitor indicate strong anti-viral effect compared with PEG-IFN/R. It is expected that PEG-IFN/R plus protease inhibitor improve the prognosis of HCV-related LDLT patients. Disclosures: The following people have

nothing www.selleckchem.com/products/LY294002.html C59 wnt cost to disclose: Satoshi Miuma, Tatsuki Ichikawa, Hisamitsu Miyaaki, Naota Taura, Kazuhiko Nakao Background: Recurrent HCV is universal after liver transplant (OLT) and progression to cirrhosis is rapid. Fibrosing cholestatic hepatitis (FCH) is a rare form of HCV recurrence associated with graft failure/death and its treatment with pegylated interferon is rarely successful and difficult to tolerate. Aims: To describe the use of an IFN-free regimen in severe recurrent hepatitis C post-OLT. Methods: One retransplant (A) and 5 primary OLT recipients (B-F) were treated: 3 with FCH(A-C), 1 with decompensated recurrent cirrhosis (D), 1 with acute lobular hepatitis (E), 1 with cholestatic lobular hepatitis. Sofos-buvir (SOF) 400 mg/day, plus Daclatasvir (DCV) 60 mg/day, were co-administered for 24 wks. Patient C also received a lead-in with peg-IFN plus ribavirin (RBV) and RBV was continued for an additional 24 wks. Pt E received one month of SOF/RBV prior to initiating SOF/DCV. Pre-treatment MELD scores ranged selleck 12-19. All had G1a. Results: Interim analysis (see table): Within 2 wks of initiating treatment with SOF/ DCV serum HCV RNA levels fell dramatically.

Within 4 wks, hyperbilirubinemia improved and liver enzymes normalized. Blood levels of tacrolimus remained stable and therapy was well tolerated. Conclusion: The rapid suppression of HCV with novel oral antiviral regimens post-OLT, reverses the changes of FCH and liver decompensation and provides great promise for severe recurrent HCV. HCV Viral Loads During Treatment * qualitative HCV RNA positive; **qualitative HCV RNA negative; NYD=not yet done Disclosures: Natalie H. Bzowej – Grant/Research Support: Gilead Sciences, Ocera Therapeutics Shobha Joshi – Grant/Research Support: Salix, Eisai; Speaking and Teaching: Merck, Gilead, Bristol-Myers Squibb George Therapondos – Grant/Research Support: Gilead, Biotest Nigel Girgrah – Speaking and Teaching: Merck, Bayer, Vertex, Gilead, Merck, Bayer, Vertex, Gilead, Merck, Bayer, Vertex, Gilead, Merck, Bayer, Vertex, Gilead Jennifer B.